Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
复制标题
DOI：
10.1182/blood-2015-06-651125
复制
发表时间：
2016-01-14
期刊：
影响因子：
20.3
通讯作者：
Hallek, Michael
中科院分区：
文献类型：
--
作者：
Fischer, Kirsten;Bahlo, Jasmin;Hallek, Michael
尽管靶向药物取得了令人鼓舞的结果，但氟达拉滨、环磷酰胺（FC）和利妥昔单抗(R)的化学免疫治疗仍然是未经治疗的慢性淋巴细胞白血病（CLL）患者的标准治疗方法。在此，我们对随机CLL8试验进行了长期随访，报告了FC和FCR治疗817例初次治疗的CLL患者的安全性和有效性。主要终点为无进展生存期（PFS）。中位随访5.9年，FCR组和FC组的中位PFS分别为56.8个月和32.9个月(风险比[HR]， 0.59； 95%可信区间[CI]， 0.5-0.69， P
Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-naive patients with CLL. The primary end point was progression-free survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for the FCR and FC group (hazard ratio[HR], 0.59; 95% confidence interval [CI], 0.5-0.69, P